肿瘤血管生长抑制剂（Ⅱ）

肿瘤血管生长抑制剂（Ⅱ）靳明林马宏敏詹新恩作者单位：第三军医大学西南医院普外科（重庆６３００３８）四、抗生素类：（一）偏端霉素Ａ的衍生物为抑制血管形成因子，能抑制肿瘤。Ｍａｒｉａｎｌ和Ｓｏｉａ等［１２，１３］在离体和活体研究了偏端霉素Ａ的新衍生物磺基...     

肿瘤血管生长抑制剂（I）

肿瘤血管生长抑制剂（Ｉ）靳明林马宏敏詹新恩作者单位：第三军医大学西南医院普外科（重庆６３００３８）恶性肿瘤的无限制侵袭性生长必须依赖持续和广泛的新生血管形成，如能抑制或破坏这些新生血管就可能阻止肿瘤的生长和转移，这是近年来肿瘤研究的一个新领域，国内外...     

肿瘤血管生成抑制剂研究进展

肿瘤生长、侵袭、转移和复发是血管生成依赖性的,以肿瘤血管生成的各个环节为靶点,研制血管生成抑制剂,可有效地抑制肿瘤的转移和复发,成为肿瘤防治的新途径。本文就目前已进入临床试验的30多种血管生成抑制剂研究进展作一综述。     

肿瘤血管生成抑制剂研究进展

肿瘤生长、侵袭、转移和复发是血管生成依赖性的,以肿瘤血管生成的各个环节为靶点,研制血管生成抑制剂,可有效地抑制肿瘤的转移和复发,成为肿瘤防治的新途径.本文就目前已进入临床试验的30多种血管生成抑制剂研究进展作一综述.     

肿瘤血管生成抑制剂研究进展张晓实综述

实体瘤的生长和转移依赖血管生成.新生血管为肿瘤细胞提供充分的氧气和营养,新生血管的内皮细胞表达多种生长因子,刺激肿瘤细胞增殖.肿瘤血管缺乏周细胞,基底膜不完整,肿瘤细胞易于进入血液循环[1].     

肿瘤血管生长抑制剂抗肿瘤作用的研究进展

目前肿瘤的抗血管生成治疗已成为肿瘤研究的热点及肿瘤治疗的新策略。迄今已发现了多种抗肿瘤血管生长抑制因子。本文就抗肿瘤血管生长抑制剂的种类和研究进展作一综述。     

靶向血管治疗肿瘤的研究进展

靶向血管治疗肿瘤已有三十年的历史,近十年来有突飞猛进的发展,现就几方面的进展简要论述.1 肿瘤区血管的发生发展及特点1.1 肿瘤细胞由休眠转为生长:没有血管,肿瘤停止在1～2mm直径以下,肿瘤细胞处于休眠状态称为无血管期(in situ),即Ⅰ期.血管长入后,肿瘤细胞分裂生长,称为有血管期,Ⅱ期.促使肿瘤由Ⅰ期向Ⅱ期转变的因素,已知的有:①微环境的改变:缺氧,缺营养,PH变酸性,NO升高等;②基因的改变:癌变时,突变型P53上调VEGF,FGF-B;野生型p53减少,内源性抑血管生长因子,凝血栓蛋白(thrombospontin,TSP-1)则下调.突变Ras基因也可上调VEGF.     

血管生成抑制剂研究新进展

肿瘤生长与转移是血管生成依赖性的,抗肿瘤血管生成可致恶性肿瘤消退,而且低毒,不易产生获得性耐药。本文综述血管生成抑制剂治疗肿瘤的新进展。     

肿瘤血管生成抑制剂TNP—470的研究进展

血管生成抑制剂ＴＮＰ－４７０具有强有力的抗肿瘤生长及抗肿瘤转移能力，本文对其作用机理、研究应用等方面的进展及存在的问题作一综述。     

Antiangiogenic therapy in the management of breast cancer

An improved understanding of the important role of angiogenesis in tumor biology has led to development of different antiangiogenic therapies. Numerous clinical studies for several antiangiogenic agents have recently been conducted in breast cancer patients and have shown clinically significant improvement in outcomes. This review focuses on current progress in the field of antiangiogenic therapy in the management of breast cancer, also highlighting issues regarding future therapeutic development that result in the greatest clinical benefits and minimizing the adverse effects.     

Antiangiogenic Chemotherapeutic Agents

The mechanism of action of anticancer chemotherapeutic agents is mainly thought to be due to a direct inhibition of tumor cell proliferation. The enhanced endothelial cell proliferation rate in tumor specimens raised the question whether therapeutic effects of chemotherapeutic agents might be at least partially attributed to an inhibition of tumor angiogenesis. Meanwhile, numerous anticancer chemotherapeutic agents were tested for their antiangiogenic potential. A few agents seem to exert consistent inhibition of tumor angiogenesis even in drug-resistant tumors. Most recent investigations on the antiangiogenic efficacy of different application schedules suggested the use of a tightly spaced, continuous application of appropriate anticancer chemotherapeutic agents. These application schedules are able to exert a strong antiangiogenic effect as indicated by an increase of apoptosis of tumor endothelial cells. Future clinical trials have to determine the therapeutic benefit of novel combination chemotherapy and alternative application schedules.     

2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate

2-Methoxyestradiol, once considered an inacitve end-metabolite of estradiol, has recently emerged as a very promising agent for cancer treatment. It is orally active in a wide range of tumor models, and inhibits tumor growth at doses showing non clinical signs of toxicity. 2ME₂ targets both the tumor cell and endothelial cell compartments by inducing apoptosis in rapidly proliferating cells and inhibiting blood vessel formation at several stages in the angiogenic cascade. Moreover, the ability of 2ME₂ to inhibit metastic spread in several models adds to its therapeutic value for cancer treatment at various stages of the disease. Though the mechanism of action is still undefined, several potential molecular targets and pathways of activation have been suggested.     

乳腺癌抗血管生成治疗:现状与前景

Tumor angiogenesis plays an important role in the growth, invasion and metastasis of breast cancer, therefore re-cently a very active area of breast cancer research involves the addition of antiangiogenic therapy. Numerous clinical studies for several antiangiogenic agents have recently been conducted in breast cancer patients and have shown clinically significant improvement in outcomes. This review gives a brief background to breast cancer angiogenesis, also focusing on current prog-ress in the field of a...     

Antiangiogenic drugs in ovarian cancer

Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.     

紫杉类药物治疗消化系肿瘤的研究进展

本文就近年来紫杉类药物在消化系统瘤包括食管癌、胃癌、大肠癌、肝癌、胆道癌、胰腺癌中的治疗情况作一综述。     

Antiangiogenic agents and late anastomotic complications

Anticancer agents targeting circulating vascular endothelial growth factor (VEGF) (e.g., bevacizumab and aflibercept) are strong angiogenesis inhibitors. As such, they may hamper the healing process, notably in the early postoperative period. Whether antiangiogenic agents may be associated with late postoperative healing complications is less known. We reviewed three cases of patients with anastomotic complications under antiangiogenic treatment occurring more than 1 year after initial surgery and we conducted a review of the literature. We report the first case of delayed anastomotic leakage which occurred under aflibercept therapy 13 months after a bilioenteric anastomosis and two cases of delayed rectal anastomotic complications associated with bevacizumab treatment 18 and 78 months after surgery. Fifteen similar cases of late gastrointestinal anastomotic complications were found in the English literature. Antiangiogenic agents are probably not deleterious to a healed wound. However, they appear to be associated with an increased risk of complications in a subgroup of patients. According to the 18 cases reported, the main risk factors appear to be low anterior resection for rectal cancer, perioperative radiotherapy, and early postoperative leak which heals through the formation of abundant and hypervascularized granulation tissue. J. Surg. Oncol. 2010;101:180–183. © 2009 Wiley‐Liss, Inc.     

Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer

As a targeted therapy, antiangiogenic treatment has been increasingly studied for advanced non-small cell lung cancer(NSCLC) and has proven effective for the treatment of advanced NSCLC. Bevacizumab, a monoclonal antibody targeting angiogenesis, is the only antiangiogenic agent approved for use in combination with first-line chemotherapy for non-squamous NSCLC. Small-molecule inhibitors targeting the tyrosine kinase receptor have also shown promise when combined with standard chemotherapeutic agents in patients with advanced NSCLC. However, unlike bevacizumab, not all other antiangiogenic agents show significant benefits when combined with chemotherapy. As for the failures of most other combinations, the combination schedule may be an important reason that has so far been overlooked in clinical trials. This article reviews the combination of angiogenic agents with chemotherapy in the treatment of NSCLC.     

氟胞苷治疗晚期乳腺癌的研究进展

本文综述氟胞苷治疗晚期乳腺癌的研究进展。单用氟胞苷治疗晚期乳腺癌有效率25 %～46 % ,与阿霉素或表阿霉素联合应用有明显的效果 ,特别是蒽环类耐药的转移性乳腺癌病人用氟胞苷 紫杉特尔治疗显示有令人鼓舞的作用。由于本品有中等度毒性及新的作用机理 ,故无论单用和联合应用治疗乳腺癌患者都值得进一步评价。